+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peptide Therapeutics Market - Global Forecast 2026-2032- Product Image
Peptide Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Peptide Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 180 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968565
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The peptide therapeutics market is undergoing significant transformation, fueled by advancements in science, manufacturing, and regulations. Senior stakeholders must navigate increasingly complex choices as peptides redefine best practices in drug development and commercialization.

Market Snapshot: Peptide Therapeutics Market Size and Growth

The global peptide therapeutics market continues its robust expansion. Recent analysis indicates that the market rose from USD 117.77 billion in 2025 to USD 128.70 billion in 2026 and is projected to reach USD 246.28 billion by 2032, reflecting a CAGR of 11.11%. Peptides are attracting considerable interest from both innovative biopharma organizations and established pharmaceutical firms. Key market drivers include innovation in peptide chemistry, novel delivery mechanisms, a growing range of clinical indications, and responsive regulatory strategies. These elements collectively position peptide therapeutics as an essential class of medicines, prompting a strategic shift for industry leaders aiming to leverage emerging opportunities and remain competitive.

Scope & Segmentation

  • Product Types: Antimicrobial peptides, peptide hormones, cell-penetrating peptides, peptide vaccines. Each type offers specific therapeutic benefits, expanding the therapeutic potential for chronic and infectious diseases, and supporting innovation in personalized treatment solutions.
  • Synthesis Methods: Synthetic solid-phase techniques and recombinant methods for complex, modified peptides. Both approaches enable scalable production while addressing purity and efficacy requirements critical in pharmaceutical manufacturing.
  • Administration Pathways: Inhalation, transdermal, injectable (including intramuscular, intravenous, subcutaneous), oral, and topical formulations. This diversity allows tailored delivery strategies that can enhance bioavailability and patient adherence across different treatment settings.
  • Clinical Applications: Infectious diseases, metabolic disorders, cardiovascular diseases, oncology. These core segments reflect the market’s relevance across a spectrum of high-priority therapeutic areas, allowing targeted development that aligns with global health needs.
  • End-users: Clinics, hospitals, research institutes. Distinct needs for storage, presentation, distribution, and training drive differentiated procurement and utilization strategies.
  • Regions Covered: Americas, Europe, Middle East & Africa, Asia-Pacific. Each region presents unique regulatory and market access challenges, requiring locally adapted commercial models and engagement with regional policy frameworks.
  • Key Technologies: Modular peptide libraries, high-throughput screening, machine learning-enabled design, advanced delivery systems, supplier and logistics management. Integrating these technologies elevates R&D efficiency and ensures a reliable flow of products from development through to patient delivery.

Key Takeaways for Senior Stakeholders

  • Scientific advancements in peptide design, synthesis, and delivery are broadening disease coverage and improving manufacturing reliability, supporting both rapid product development and positive patient outcomes.
  • Integrated clinical development models utilizing adaptive trial designs and biomarkers reduce late-stage risk and create efficient regulatory review pathways, accelerating cycle times.
  • Strategic partnerships between biotech firms, established pharmaceutical companies, and contract manufacturers support platform innovation and robust development pipelines grounded in intellectual property protection.
  • Procurement teams are adopting more resilient sourcing approaches such as nearshoring and dual-sourcing to manage volatility from global trade disruptions and changing tariff structures.
  • Region-specific regulations shape market entry tactics and necessitate proactive engagement with payers and regulators, helping align evidence needs with reimbursement priorities.
  • Precise segmentation by product class, indication, and territory enables alignment of R&D and commercial activities with stakeholder expectations and operational capabilities.

Tariff Impact on Peptide Therapeutics Market

Shifts in tariff and trade compliance environments have increased value chain complexity in peptide manufacturing. Firms are counteracting these changes by enhancing supplier diversity, investing in customs-related capabilities, and implementing dual-sourcing models. These strategies maintain continuity, minimize risks of delayed shipments, and help manage costs arising from regulatory changes affecting cross-border trade. Senior teams are advised to monitor tariffs closely to support agile procurement and logistics planning.

Peptide Therapeutics Market: Methodology & Data Sources

This report combines insights from structured interviews with industry experts, a comprehensive review of patent and clinical documentation, and triangulation from secondary sources. An iterative approach to validation ensures all findings reflect operational realities, regulatory standards, and the most relevant best practices. The methodological rigor delivers pragmatic, evidence-based guidance for strategic planning.

Why This Report Matters to Decision-Makers

  • Clarifies where technological advances and resilient supply chain approaches intersect with regulatory shifts to shape successful peptide programs.
  • Enables leadership to adapt R&D, procurement, partnership, and commercialization strategies to evolving market demands and stakeholder expectations.
  • Supports proactive risk management by linking scientific innovation with manufacturing scalability and dynamic payer expectations.

Conclusion

Organizations aligning early design, robust sourcing, adaptive regulatory processes, and strategic partnerships are positioned to maximize the value of peptide therapeutics. Ongoing industry transformation requires a multi-faceted approach, ensuring clinical impact and commercial effectiveness for all stakeholders.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Peptide Therapeutics Market, by Product Type
8.1. Antimicrobial Peptides
8.2. Cell Penetrating Peptides
8.3. Peptide Hormones
8.4. Peptide Vaccines
9. Peptide Therapeutics Market, by Synthesis Technique
9.1. Recombinant Peptides
9.2. Synthetic Peptides
10. Peptide Therapeutics Market, by Route Of Administration
10.1. Inhalation
10.2. Injectable
10.2.1. Intramuscular
10.2.2. Intravenous
10.2.3. Subcutaneous
10.3. Oral
10.3.1. Capsule
10.3.2. Liquid
10.3.3. Tablet
10.4. Topical
10.5. Transdermal
11. Peptide Therapeutics Market, by Application
11.1. Cardiovascular Diseases
11.1.1. Heart Failure
11.1.2. Hypertension
11.2. Infectious Diseases
11.2.1. Hepatitis
11.2.2. Hiv
11.2.3. Influenza
11.3. Metabolic Disorders
11.3.1. Diabetes
11.3.2. Obesity
11.4. Oncology
11.4.1. Breast Cancer
11.4.2. Lung Cancer
11.4.3. Melanoma
12. Peptide Therapeutics Market, by End User
12.1. Clinics
12.2. Hospitals
12.3. Research Institutes
13. Peptide Therapeutics Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Peptide Therapeutics Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Peptide Therapeutics Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Peptide Therapeutics Market
17. China Peptide Therapeutics Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Amgen Inc.
18.6. AstraZeneca PLC
18.7. Bachem Holding AG
18.8. Bristol Myers Squibb Company
18.9. Eli Lilly and Company
18.10. GlaxoSmithKline plc
18.11. Ipsen S.A.
18.12. Merck & Co., Inc.
18.13. Novartis AG
18.14. Novo Nordisk A/S
18.15. Pfizer Inc.
18.16. Sanofi S.A.
18.17. Takeda Pharmaceutical Company Limited
18.18. Teva Pharmaceutical Industries Ltd.
18.19. Zealand Pharma A/S
List of Figures
FIGURE 1. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIAL PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE HORMONES, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE HORMONES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHETIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHETIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OBESITY, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OBESITY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OBESITY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 122. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 123. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 124. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 125. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 126. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 127. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 166. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 167. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 168. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 169. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 170. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 171. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 172. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 173. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 174. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 175. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 184. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 186. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 187. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 189. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 190. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 191. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 192. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 193. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 194. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 195. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 196. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 197. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 198. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 199. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 206. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 207. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 208. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 209. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 210. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 211. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 212. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 213. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 215. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 216. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 217. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 218. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 219. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 220. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 221. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 222. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 223. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 224. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 225. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 226. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 227. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 228. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 229. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 230. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 231. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 232. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 233. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 234. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 235. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 236. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 249. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 250. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 251. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 252. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 253. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 254. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 255. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 256. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 257. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 258. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 259. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 260. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 261. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 262. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 263. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 264. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 265. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 266. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 267. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 268. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 269. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 270. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 271. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 272. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 273. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 274. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 275. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 276. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 277. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 278. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 279. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 280. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 281. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 282. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 283. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 284. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 285. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 286. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 287. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 288. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 289. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 290. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 291. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 292. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 293. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 294. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 295. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 296. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 297. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 298. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 299. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 300. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNIQUE, 2018-2032 (USD MILLION)
TABLE 301. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 302. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 303. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 304. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 305. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 306. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 307. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 308. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 309. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Peptide Therapeutics market report include:
  • Amgen Inc.
  • AstraZeneca PLC
  • Bachem Holding AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Ipsen S.A.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zealand Pharma A/S

Table Information

Report AttributeDetails
No. of Pages180
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 128.7 Billion
Forecasted Market Value ( USD ) by 2032 $ 246.28 Billion
Compound Annual Growth Rate11.1%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Peptide Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Peptide Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Peptide Therapeutics Market Size, Share, Trends and Forecast by Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, and Region, 2025-2033 - Product Image

Peptide Therapeutics Market Size, Share, Trends and Forecast by Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, and Region, 2025-2033

  • Report
  • 139 Pages
  • Global
From
Peptide Therapeutics Market: Industry Trends and Global Forecasts, Till 2040 - Distribution by Type of Peptide, Route of Administration, Key Therapeutic Area and Geographical Regions - Product Image

Peptide Therapeutics Market: Industry Trends and Global Forecasts, Till 2040 - Distribution by Type of Peptide, Route of Administration, Key Therapeutic Area and Geographical Regions

  • Report
  • 250 Pages
  • Global
From
Peptide Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Peptide Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Peptide Therapeutics Market Report 2025 - Product Image

Peptide Therapeutics Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Peptide Therapeutic Market

The Peptide Therapeutic market is a subset of the Proteomics industry, which focuses on the study of proteins and their functions. Peptide Therapeutics are a type of drug that are composed of short chains of amino acids, and are used to treat a variety of diseases. These drugs are typically used to target specific proteins in the body, and can be used to treat conditions such as cancer, diabetes, and autoimmune diseases. Peptide Therapeutics are often used in combination with other drugs, such as chemotherapy, to maximize their effectiveness. The Peptide Therapeutic market is highly competitive, with many companies developing and marketing these drugs. Some of the major players in the market include Amgen, Merck, Novartis, Pfizer, and Sanofi. Other companies such as AbbVie, AstraZeneca, and Eli Lilly are also active in the market. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.